Cns Pharmaceuticals Inc (CNSP)

$6.19 +1.10 (21.61%)
Market Cap 2.32M
Revenue (ttm) 0.00
Net Income (ttm) -14.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 81,900
Avg Vol 27,242
Day's Range N/A - N/A
Shares Out 455,000.00
Stochastic %K 45%
Beta 2.64
Analysts Hold
Price Target $7.00

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 800-946-9185
Address:
2100 West Loop South, Suite 900, Houston, United States
StockHounding
StockHounding Aug. 19 at 1:32 AM
$VTAK and $FMST were solid today Come get alerts earlier Our alerts are more valuable than paid discords I can assure you We nailed $ILLR and $CNSP as well
0 · Reply
artinB
artinB Aug. 18 at 8:19 PM
$CNSP very good day, any good news will send this to 10-15$
1 · Reply
ClarityOfPurpose
ClarityOfPurpose Aug. 18 at 7:15 PM
$CNSP Silly people. Just day trader manipulation. Don’t be left as a bag holder.
0 · Reply
makedatbread88
makedatbread88 Aug. 18 at 5:55 PM
$CNSP low floater has volume coming in keep an eye
0 · Reply
artinB
artinB Aug. 18 at 4:27 PM
$CNSP @FonsieTrader check out $CNSP , cash value 25$ trading 5s
0 · Reply
artinB
artinB Aug. 18 at 4:11 PM
$CNSP 10-15$ possible with a little volume, float is less than 500k
0 · Reply
artinB
artinB Aug. 18 at 3:02 PM
$CNSP don’t sleep on this one, easy 10-15 spike, 25$ cash value
0 · Reply
Camelinvesting
Camelinvesting Aug. 17 at 2:22 PM
$CNSP any hope this reversal back to 7$ ?
1 · Reply
d_risk
d_risk Aug. 16 at 10:52 PM
$CNSP - CNS Pharmaceuticals, Inc. - 10Q - Updated Risk Factors CNSP warns of new risks tied to potential Nasdaq delisting, citing past compliance issues and ongoing challenges meeting listing requirements, which could hurt stock liquidity, financing options, and investor confidence. #Biotechnology #InvestorConfidence #NasdaqDelisting #StockLiquidity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/CNSP/10-Q/2025-08-14
1 · Reply
kl7777
kl7777 Aug. 16 at 3:47 PM
$CNSP To note, I left a reply for the latest post @cns_pharma on X account for those holding. Things I asked were update on Berubicin,if it's pending, something before result of phase 2 study on TPI-287 & purchase of shares by mgmt. Hope someone knows where I'm coming from, regarding writing posts.
0 · Reply
Latest News on CNSP
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 8:05 AM EDT - 4 days ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 5 days ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 weeks ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 18, 2025, 8:00 AM EDT - 4 weeks ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jul 9, 2025, 9:32 AM EDT - 5 weeks ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 24, 2025, 9:15 AM EDT - 2 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

Jun 5, 2025, 8:05 AM EDT - 2 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:05 AM EDT - 3 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 9:35 AM EDT - 3 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025, 7:00 AM EDT - 3 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Apr 1, 2025, 8:05 AM EDT - 5 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 12:05 PM EDT - 5 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Mar 25, 2025, 8:00 AM EDT - 5 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 26, 2025, 9:05 AM EST - 6 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 20, 2025, 9:00 AM EST - 6 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 6 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 18, 2025, 9:00 AM EST - 6 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 10, 2025, 8:00 AM EST - 6 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Dec 5, 2024, 9:10 AM EST - 9 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 25, 2024, 9:00 AM EST - 9 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 18, 2024, 8:55 AM EST - 9 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 9:10 AM EST - 9 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 4, 2024, 9:15 AM EST - 10 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 1, 2024, 9:00 AM EDT - 10 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 23, 2024, 2:50 PM EDT - 10 months ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 10, 2024, 9:00 AM EDT - 11 months ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Oct 8, 2024, 9:15 AM EDT - 11 months ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 23, 2024, 9:00 AM EDT - 11 months ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Top 5 Health Care Stocks That Are Preparing To Pump In February

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Dec 18, 2023, 8:35 AM EST - 1 year ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Dec 6, 2023, 9:00 AM EST - 1 year ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

StockHounding
StockHounding Aug. 19 at 1:32 AM
$VTAK and $FMST were solid today Come get alerts earlier Our alerts are more valuable than paid discords I can assure you We nailed $ILLR and $CNSP as well
0 · Reply
artinB
artinB Aug. 18 at 8:19 PM
$CNSP very good day, any good news will send this to 10-15$
1 · Reply
ClarityOfPurpose
ClarityOfPurpose Aug. 18 at 7:15 PM
$CNSP Silly people. Just day trader manipulation. Don’t be left as a bag holder.
0 · Reply
makedatbread88
makedatbread88 Aug. 18 at 5:55 PM
$CNSP low floater has volume coming in keep an eye
0 · Reply
artinB
artinB Aug. 18 at 4:27 PM
$CNSP @FonsieTrader check out $CNSP , cash value 25$ trading 5s
0 · Reply
artinB
artinB Aug. 18 at 4:11 PM
$CNSP 10-15$ possible with a little volume, float is less than 500k
0 · Reply
artinB
artinB Aug. 18 at 3:02 PM
$CNSP don’t sleep on this one, easy 10-15 spike, 25$ cash value
0 · Reply
Camelinvesting
Camelinvesting Aug. 17 at 2:22 PM
$CNSP any hope this reversal back to 7$ ?
1 · Reply
d_risk
d_risk Aug. 16 at 10:52 PM
$CNSP - CNS Pharmaceuticals, Inc. - 10Q - Updated Risk Factors CNSP warns of new risks tied to potential Nasdaq delisting, citing past compliance issues and ongoing challenges meeting listing requirements, which could hurt stock liquidity, financing options, and investor confidence. #Biotechnology #InvestorConfidence #NasdaqDelisting #StockLiquidity #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/CNSP/10-Q/2025-08-14
1 · Reply
kl7777
kl7777 Aug. 16 at 3:47 PM
$CNSP To note, I left a reply for the latest post @cns_pharma on X account for those holding. Things I asked were update on Berubicin,if it's pending, something before result of phase 2 study on TPI-287 & purchase of shares by mgmt. Hope someone knows where I'm coming from, regarding writing posts.
0 · Reply
kl7777
kl7777 Aug. 15 at 10:27 PM
$CNSP Need to finish today strong.
0 · Reply
artinB
artinB Aug. 15 at 8:43 PM
$CNSP nano float 25$ cash value post rs dropped on low volume
0 · Reply
artinB
artinB Aug. 15 at 8:40 PM
$CNSP this will fly soon
2 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 15 at 7:56 PM
TinyGemsBreaks – $CNSP Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial https://ibn.fm/X5LZr
0 · Reply
kl7777
kl7777 Aug. 15 at 7:49 PM
$CNSP I understand people don't like the company, including me, but we should not let the shorts control the price, dropping the price. Again, add shares if you can so price can rise higher to get out w/ smaller losses.
0 · Reply
simonsteve
simonsteve Aug. 15 at 7:33 PM
$CNSP yeah bring it all the way to zero you mofos scammers scamming people their hard earned money
0 · Reply
shock89
shock89 Aug. 15 at 7:27 PM
$CNSP New low everyday
0 · Reply
artinB
artinB Aug. 15 at 7:03 PM
$CNSP dropping on low volume, buy what you can. Float is less than 500k
0 · Reply
JimBull
JimBull Aug. 15 at 6:44 PM
$CNSP adding more, $12.1M cash in hand!
1 · Reply
shock89
shock89 Aug. 15 at 6:24 PM
$CNSP Keep buying, keep decreasing.
0 · Reply
Samiam69
Samiam69 Aug. 15 at 6:19 PM
$CNSP run
0 · Reply
Samiam69
Samiam69 Aug. 15 at 5:58 PM
$CNSP 💩💩💩
0 · Reply